Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 13Myeloid 7Thoracic 1Other solid neoplasm 1Gynecologic 1Genitourinary 1Gastrointestinal 1CNS 1Breast 1

Conditions

Pancreatic Neoplasms 1

Interventions

Oxaliplatin 1004Fluorouracil 800Capecitabine 765Gemcitabine 651Leucovorin 559Irinotecan 537Bevacizumab 513Radiotherapy 460Cisplatin 441Drug Therapy 298Cetuximab 280Surgical Procedures, Operative 229Paclitaxel 228S 1 (combination) 218pembrolizumab 206Docetaxel 199130-nm albumin-bound paclitaxel 196Nivolumab 193sintilimab 191Radiosurgery 190lenvatinib 181Folfox protocol 179Sorafenib 178Albumin-Bound Paclitaxel 173apatinib 170tislelizumab 161camrelizumab 160Neoadjuvant Therapy 158Blood Specimen Collection 154durvalumab 148

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × bosutinib × Gastrointestinal × Clear all
NCT01025570 2014-05-09

A Study Evaluating Gemcitabine Plus Bosutinib for Patients With Resected Pancreatic Cancer

University of California, San Francisco

Phase 1 Terminated
3 enrolled
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡